ERYMICIN 200 Injection (Erymicin 200) is a solution that contains erythromycin for injection on juvenile and adult Salmonids. Erymicin 200 is only available for purchase through Syndel USA. The primary goal of field studies conducted under INAD #12-781 is to evaluate the efficacy of erythromycin for 1) controlling mortality caused by BKD (causative agent: Renibacterium salmoninarum) in salmonid species; and 2) control the vertical transmission of R. salmoninarum from BKD positive female broodstock to eggs/progeny. Fish treated for controlling mortality can be treated a single time with Erymicin 200 Injection at 10 – 25 mg erythromycin per kilogram (kg) fish body weight. Fish treated to control vertical transmission can be treated 1 to 3 times with Erymicin 200 at 10 – 25 mg erythromycin per kg fish body weight with a minimum injection interval of 21 days. The total dosage will not exceed 75 mg erythromycin per kilogram (kg) fish body weight over 3 injections. Adherence to a 60-day Investigational withdrawal period is required for all fish treated with Erymicin 200 under this INAD. To participate in the INAD Program for Erymicin 200 visit the data collecting site.
Please read the Study Protocol prior to any treatments. It contains the protocol, MSDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson .
INAD objective/purpose: Collect supportive and/or pivotal data needed to establish the effectiveness of erythromycin to 1) control mortality caused by bacterial kidney disease (BKD; causative agent: Renibacterium salmoninarum) in salmonid species; and 2) control the vertical transmission of R. salmoninarum from BKD positive female broodstock to eggs/progeny.
Erythromycin (Erymicin 200 Injectable)
1441 W Smith Rd,
Ferndale, WA 98248 USA
Target pathogen(s): Bacterial kidney disease (BKD; causative agent: Renibacterium salmoninarum)
Method of administration: IM or IP injection only
Investigational Withdrawal period:
Required test parameters:
Limitations or restrictions on use of drug:
Required INAD fee: $700/facility/year
AADAP Contact Information:
Ms. Bonnie Johnson, FWS-AADAP